KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2016 - 2017)

Regeneron Pharmaceuticals (REGN) has disclosed Interest & Investment Income for 9 consecutive years, with -$6.0 million as the latest value for Q4 2017.

  • For Q4 2017, Interest & Investment Income fell 114.92% year-over-year to -$6.0 million; the TTM value through Dec 2017 reached -$25.1 million, down 249.12%, while the annual FY2017 figure was -$25.1 million, 249.12% down from the prior year.
  • Interest & Investment Income hit -$6.0 million in Q4 2017 for Regeneron Pharmaceuticals, up from -$6.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $2.1 million in Q3 2015 and bottomed at -$18.2 million in Q4 2015.
  • Average Interest & Investment Income over 5 years is -$2.5 million, with a median of -$873500.0 recorded in 2016.
  • Year-over-year, Interest & Investment Income soared 105.48% in 2014 and then plummeted 1566.67% in 2016.
  • Regeneron Pharmaceuticals' Interest & Investment Income stood at -$2.3 million in 2013, then skyrocketed by 174.24% to $1.7 million in 2014, then crashed by 1186.11% to -$18.2 million in 2015, then surged by 84.58% to -$2.8 million in 2016, then plummeted by 114.92% to -$6.0 million in 2017.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at -$6.0 million, -$6.2 million, and -$5.4 million for Q4 2017, Q3 2017, and Q2 2017 respectively.